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Abstract
Background: Classical galactosaemia (OMIM #230400) is a rare disorder of carbohydrate metabolism caused by
deficiency of the galactose-1-phosphate uridyltransferase enzyme. The pathophysiology of the long-term complications,
mainly cognitive, neurological and female fertility problems, remains poorly understood. Current clinical methods of
biochemical monitoring lack precision and individualization with an identified need for improved biomarkers for this
condition.
Methods: We report the development and detailed validation of an automated ultraperformance liquid chromatogra-
phy N-glycan analytical method of high peak resolution applied to galactose incorporation into human serum IgG.
Samples are prepared on 96-well plates and the workflow features rapid glycoprotein denaturation, enzymatic glycan
release, glycan purification on solid-supported hydrazide, fluorescent labelling and post-labelling clean-up with
solid-phase extraction.
Results: This method is shown to be accurate and precise with repeatability (cumulative coefficients of variation) of 2.0
and 8.5%, respectively, for G0/G1 and G0/G2 ratios. Both serum and processed N-glycan samples were found to be
stable at room temperature and in freeze–thaw experiments.
Conclusions: This high-throughput method of IgG galactose incorporation is robust, affordable and simple.
This method is validated with the potential to apply as a biomarker for treatment outcomes for galactosaemia.
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Introduction
Classical galactosaemia (OMIM 230400) is a rare dis-
order of carbohydrate metabolism caused by galactose-
1-phosphate uridyltransferase (GALT) deficiency (EC
2.7.7.12).1 Deficiency of GALT results in toxic build-up
of intermediates of the galactose metabolism (Leroir)
pathway, such as galactose-1-phosphate (Gal-1-P) and
galactitol.1 The only available treatment option is a
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long-term galactose-restricted diet. Dietary interven-
tion can be lifesaving in the neonate; however, long-
term complications persist in treated adult patients to
include significant cognitive impairment, decreased
bone mineral density and infertility in females.
These complications are regardless of genotype or age
at the onset of treatment.1–5
Recently, a European Consortium (GalNet) devel-
oped new consensus clinical guidelines for the manage-
ment of classical galactosaemia.6 It was identified in the
development of these guidelines that there is a great
need for improved biomarkers to assess the effective
treatment of galactosaemia and for follow-up monitor-
ing. The current tests for measuring RBC Gal-1-P and
urinary galactitol concentrations, apart from predicting
gross deviations from diet and monitoring initial
decreases of RBC Gal-1-P in the neonate, do not
reveal milder deviations or correlate with clinical out-
come.7–11 High intraindividual variability of urinary
galactitol and RBC Gal-1-P concentrations limits
their reliability as a monitoring test.12
The presence of profound N-glycan assembly defects
in the intoxicated galactosaemia neonate has been well
characterized using the study of transferrin.13–15 Our
group has identified similar N-glycan assembly defects
in neonates using serum immunoglobulin G (IgG) and
has identified ongoing significant N-glycan-processing
defects in treated young children and adults with gal-
actosaemia.11,16–18 The accumulation of toxic galactose
intermediates coupled with deficiency of pathway prod-
uct is proposed to contribute to the development of
these complications proposed to be a result of compet-
itive inhibition of glycosyltransferases19 and a shortage
of end-product UDP-hexose sugars.20 These abnormal-
ities lead to disruption of glycosylation in the post-
translational modification of protein and lipids.21–23
Human serum IgG is the most abundant circulating
N-glycan glycoprotein.24 The use of glycan profiling is
now increasingly used as a prognostic and diagnostic
biomarker in a number of diseases, including cancer,
diabetes and rheumatoid arthritis.25–27
The development and analytical validation steps of
an automated, high-throughput IgG sample prepara-
tion platform with hydrophilic interaction ultraper-
formance liquid chromatography (HILIC-UPLC)
detection has been well developed by our research
group and applied to the study of cancer, diabetes
and rheumatoid arthritis.28–30 In our studies in galac-
tosaemia, we have developed a method to study the
incorporation of galactose residues into the N-glycome
of patients with galactosaemia.
The heterogeneous total glycan pool incorporated
into the IgG molecule can be classified into three
sets (G0, G1 and G2), depending on the number of
galactose residues in the outer arms of the biantennary
glycans. In our earlier studies, we documented an
increase in non-galactosylated (G0) and monogalactosy-
lated (G1) N-glycan structures with decreased digalacto-
sylated structures (G2) in diet-restricted galactosaemia
patients (children and adults), which indicates continued
N-glycan-processing defects despite dietary galactose
restriction in these patients.11,17,18,31,32 Furthermore,
we noted improvement in glycosylation with moderate
galactose diet liberalization in a subset of adults and
children.11,33
We previously reported an improved automated
robotic HILIC-UPLC N-glycan analysis applied to the
measurement of IgG N-glycan galactose incorporation
ratios (G0/G1 and G0/G2 incorporation ratios) and
identified statistically significant differences between 40
classical galactosaemia adults and 81 matched healthy
controls.31,34
This paper now outlines the further development
and analytical validation steps of this automated,
high-throughput IgG sample preparation platform
with HILIC-UPLC detection for the measurement of
IgG N-glycan galactose incorporation, which we pro-




The reagents and buffers used in this method are as
follows.
1. Binding buffer: 0.1 mol/L sodium phosphate buffer
(PBS), 0.15 mol/L NaCl, pH 7.4.
2. Washing buffer: binding buffer containing 1%
triton-X, pH 7.4.
3. Elution buffer: 0.2 mol/L Glycine–HCl, pH 2.5.
4. Regeneration buffer: Elution buffer containing 1%
triton-X.
5. Neutralization buffer: 1mol/L tris-HCL buffer
pH 9.0.
6. Denaturation buffer: 100mmol/L ammonium
bicarbonate, 50mmol/L dithiothreitol, 0.1%
sodium dodecyl sulphate.
7. Iodacetamide solution: 100 mmol/L IAA.
8. PNGase solution: PNGase (Prozyme glyco N-glyca-
nase) in 1 mol/L ammonium bicarbonate, pH 8.0.
9. 2-AB Labelling mix: 350 mmol/L anthranilamide,
1M sodium cyanoborohydride in acetic acid/
dimethyl sulfoxide (30:70 v/v).
10. Guanidine: 2 mol/L guanidine hydrochloride.
11. Triethylamine (TEA): 2% TEA in methanol
(MeOH).
12. 2% Acetic acid solution: 2% acetic acid in aceto-
nitrile (MeCN).
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13. Ammonium formate: 50 mmol/L in water.
14. Reagent grade MeOH and MeCN and ultrapure
water type 1 (18.2 MX.cm at 25C).
Quality control samples and
calibrating materials
The following samples were used for experimentation:
Normal human serum (NHS, Merck Millipore,
Temcula, CA), a filtered human serum pool collected
from the clot of normal healthy humans, was used as
the analyte-containing matrix across all experiments
and general quality control across the study. For the
purpose of this project, it was named ‘control sample’.
2-AB labelled Mannose-3 (Man3-2AB) glycan
(Carbosynth Ltd, Berkshire, UK) was used as an inter-
nal standard (IS) for the UPLC linearity experiment.
2-AB labelled dextran (Waters, Massachusetts,
USA) was used as an external standard to identify
peaks using glucose units (GUs).
Patient and control samples
The patient samples were obtained from a cohort
of five classical galactosaemia Irish adults (three
males, two females), all homozygous for the
c.563A>G (p.Q188R) mutation. These patient
samples were used for the repeatability, stability and
biological replicate studies. Ethical approval for this
study was obtained from the Ethics Committee of the
Mater Misericordiae University Hospital, Dublin,
Ireland. The samples were non-fasting, taken during
normal clinical visits. The control samples were
obtained from a pool of healthy adult volunteers.
Sample preparation and UPLC analysis. IgG isolation: (see
Figure 1 for diagrammatic steps and reagents section
for detailed description of reagents):
Apart from centrifugation steps, the following was
carried out on a Starlet Microlab robotic liquid han-
dling platform (Hamilton, Bonaduz, Switzerland)
equipped with eight pipetting channels, a heated orbital
shaker and vacuum manifold. Protein G plate wells
(Thermo Scientific, Massachusetts, USA) were pre-
washed with 500 lL of binding buffer. The buffer was
removed by vacuum and 50lL of serum samples were
diluted in 50 lL of binding buffer (1:1 ratio), added to
the protein G plate and incubated at room temperature
(RT) for 30min at 700 r/min on the orbital shaker. The
buffer was removed and the IgG washed five times with
475 lL of washing buffer. The wash sequence was
repeated with five washes of binding buffer. A 2mL
collection block (CB) containing 50 lL of neutraliza-
tion buffer was then inserted into the vacuum mani-
fold. Elution buffer (200 lL) was added to the protein
G wells and incubated at RT for 2min without agita-
tion. The IgG-rich flow-through was captured in the
CB under vacuum. An additional 200 lL of elution
buffer was added to the resins and the cycle repeated.
The CB was briefly centrifuged to remove bubbles and
the filtrate was transferred to an Acroprep Advance
10 kDa filter plate (AAFP) (Pall, New York, USA).
The elution buffer was removed from the AAFP by
centrifugation at 3700 g for 15min at RT. The
AAFP was then spun at 3700 g for 30min leaving
IgG as the retentate. Denaturation buffer (40 lL) was
added to each well and the AAFP was incubated at
70C for 20min at 700 r/min under an antievaporation
lid. After cooling, 10 lL of iodoacetamide solution was
immediately added to the wells and the AAFP incubat-
ed at RT for 30min at 700 r/min. The solvents were
removed by centrifugation at 3700 g for 10min.
Water (50 lL) and peptide: N-glycosidase F (10 lL)
(PNGase, New England Biolabs, Massachusetts,
USA) were added and the AAFP was incubated at
37C for 2 h at 700 r/min. In the meantime, resins
may be regenerated with six washes of regeneration
buffer, five washes of elution buffer and four washes
of binding buffer with intermittent agitations of 1min
at 700 r/min. The AAFP was centrifuged at 3700 g
for 15min and released N-glycans were collected in a
Greiner plate (Greiner Bio-One, Kremsmünster,
Austria). An additional 20 lL of water was added to
the AAFP with 5min incubation at RT and the flow
through centrifuged into the same Greiner plate at
3700 g for 20min.
N-glycan clean up and labelling
Wells of a SolvinertTM chemically inert filter plate
(Millipore, Massachusetts, USA) were washed with
100 lL of MeOH and vacuumed. A solution of
Ultralink hydrazide resin beads in water (Thermo
Scientific, Massachusetts, USA) was agitated at RT
for 5min at 400 r/min. Agitating solution (40 lL) was
transferred to each well and the solvent was removed
under vacuum. The beads were washed with 200 lL of
MeOH, 200 lL of water and 200 lL of 95% MeCN.
The SolvinertTM membranes were sealed by evaporat-
ing solvent at 80C for 8min. The plate was then blot-
ted on filter paper and the plate cooled for 1min. One
hundred and eighty microlitres of 2% acetic acid
(AcOH) in MeCN were added to the SolvinertTM
plate followed by 20lL of glycan solution from part
1 (Greiner plate solution). The N-glycans were cap-
tured on the solid support by incubation at 80C for
1 h at 700 r/min. The beads were wetted with another
100 lL of 2% AcOH solution and the incubation con-
tinued for 10min. The solvents were removed under
vacuum, and the supported glycans were washed twice
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with 300lL of MeOH, twice with 200lL of guanidine
HCL), twice with 200lL of water, and twice with
200lL of MeOH. The plate was blotted again. MeOH
(180lL) and acetic anhydride (20lL) (reagent grade)
were then added to the wells which were incubated at
RT for 30min at 600 r/min. The solvent was removed
under vacuum and the supported glycans were washed
twice with 200lL of MeOH, twice with 200lL of water
and twice with 200lL of 95% MeCN. After vacuuming
out the liquid, the remaining solvent was evaporated off
at RT for 5min. The glycans were released from solid
support with 175lL of 2% AcOH solution and 25lL of
20% MeCN in water, at 60C for 30min at 700 r/min
followed by another hour of incubation at 60C at
400 r/min. After cooling for 5min, 50lL of 2-AB label-
ling mix was added to the mixture which was incubated
at 65C for 2 h at 800 r/min. The solution was then
transferred to a 2mL CB containing 1mL of 95%
MeCN per well.
HypersepTM Diol Cartridges (Thermo Fisher
Scientific, Massachusetts, USA) were pre-equilibrated
with 1mL water and vacuumed followed by 1mL of
MeCN which was vacuumed through. The glycans and
separated beads were transferred from the CB to the
cartridges which were washed three times with 750 lL
of MeCN. The purified glycans were eluted from the
cartridges into a CB under vacuum with two rounds of
200 lL of 20% MeCN solution which was incubated
for 5min before each elution.
Ultraperformance liquid chromatography
The N-glycan solution was either stored (at 4C or
40C) or dried in a rotary vacuum at 37C. The gly-
cans were re-dissolved in 6 lL of water and 14 lL of
Figure 1. Processing of human serum IgG for N-glycan analysis.
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MeCN (30/70% solution) giving a 20lL solution. Of this,
19lL was injected onto the column for a 20min runtime.
The HILIC-UPLC was carried out on a BEH Glycan
column on an Acquity UPLC (Waters, Massachusetts,
USA) equipped with a fluorescence detector. Solvent A
used was 50 mM ammonium formate solution, pH 4.4.
Solvent B was acetonitrile (HPLC grade). The column
temperature was set to 40C. The following conditions
were used: 20min method using a linear increasing gradi-
ent of 30–70% solvent A and a linear decreasing gradient
of solvent B at 0.561 mL/min. The samples were injected
in 70% acetonitrile and 30% water. The fluorescence was
measured at 420 nm with excitation at 330 nm and all
analytical peaks resolved within 12min. The system was
calibrated using an external standard of hydrolysed, 2-AB-
labelled glucose oligomers (Waters, Massachusetts, USA)
to create a dextran ladder with retention times of all iden-
tified peaks expressed as GU.30,34
Peak integration
Twenty-eight N-glycan peaks (GP), previously charac-
terized by UPLC and mass spectrometry,35 were iden-
tified and grouped according to galactose content. The
peak % areas of agalactosylated (G0), monogalactosy-
lated (G1) and digalactosylated (G2) structures were
determined and the specific G-ratios (G0/G1) and
(G0/G2) were calculated (Figure 2). This provided a
qualitative measurement of the incorporation of galac-
tose into IgG N-glycans.18,31 The G-ratios were inter-
preted for clinical evaluation as specific quantitative
values of patient IgG N-glycan galactose incorporation
compared with control G-ratios.11,18
The data analysis was completed using Empower 3
Software, and the results were compared to Glycobase
using the dextran ladder and GU values (http://glyco
base.nibrt.ie) that allows computer-assisted preliminary
structural assignments.37,38
Figure 2. Grouping of peaks for G-ratio assignment. (a) UPLC IgG N-glycan chromatograph: G0¼ Sum of peak areas in G0 region
(glycan peaks [GP] 1–6). G1¼ Sum of peak areas in G1 regions (GP 7–12 and 18–19). G2¼ Sum of peak areas in G2 regions
(GP 13–17 and 20–28, excluding GP 24 at approx. 10 min). For GX, X¼ number of galactose moieties. (b) Examples of N-glycan
species within each region. Galactose sugars represented by gold circles according to legend (c).36
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Repeatability
Control samples at volumes of 12.5, 50.0 and 100.0 lL
(lower limit of quantification [LLOQ], clinical decision
point and upper limit of quantification [ULOQ],
respectively) were analysed in quintuplets, five times
over five separate time periods. For this method,
50 lL was found to be sufficient to overcome the
signal to noise ratios during UPLC detection and sufficient
flow rates through the ultrafiltration plate under vacuum/
centrifugation as demonstrated previously.34 Thus, 50lL
was determined to be the clinical decision point. The
patient sample was run at one volume (50.0lL) in quintu-
plets five times over five separate periods.
Linearity of the waters acquity H-class UPLC system
Man3–2-AB (0.83 ng/lL) was spiked at five quantities
ranging from 1 to 5lL (0.83–4.17 ng) into 2-AB
labelled dried glycans extracted from 50 lL of patient
serum samples, bringing the water volume to 6 lL.
Fourteen microlitres of MeCN were added to give a
20 lL of injection mixture. The samples were analysed
in duplicate. The peak area versus concentration
data treated by least square linear regression
analysis was performed on the Man3–2-AB peaks
to check for a linear response in fluorescence of the
UPLC apparatus.
Linearity of the automated IgG N-glycan
purification and labelling platform
Five control serum concentrations running from
LLOQ up to the ULOQ were tested in triplicate to
give the reportable range of the method.
Limit of quantification
The limit of quantification was defined as the serum
volume where the smallest peak had an EP s/n <10
and coefficient of variation (CV)< 20% of three sam-
ples. Blank segments of each chromatogram between
14 and 15min were used as the blank. The lowest
volume tested was 12.5 lL (25% of clinical decision
point) and 100.0 lL was the highest volume tested
(maximum specified capacity of protein G plate). For
the LLOQ and ULOQ, 12.5, 37.5, 50.0, 62.5, 70.0 and
100.0 lL control samples were tested in triplicate.
Stability and freeze–thaw cycles
Stability at 4C
A control sample and one patient sample were stored in
4C for up to 40 days. They were analysed in duplicate
at five different time points.
Freeze/thaw stability
A freeze–thaw experiment was performed on control
and on one patient sample. The samples were thawed
for 2 h at RT and refrozen at 40C. Four cycles were
repeated. The samples were analysed in duplicate.
Stability between steps
The samples were tested for stability at 4C and 40C
up to one week following glycan release from IgG and
tested in similar conditions after glycan dry down (pre-
UPLC). This was necessary for managing day to day
hardware availability in a busy lab.
Cross-column stability
The sample sets were run on three different BEH Glycan
1.7 lM 2.1 150 mm columns to test for repeatability
(the column serial numbers were: 01243327416632,
01573611818047 and 01623635718339).
UPLC dock preinjection stability
The samples were tested for preinjection incubation
periods up to a runtime of 45.5 h.
Crossover
Sample crossover of the UPLC needle was checked
by processing three water blanks alongside three high
concentration control samples (100 lL). Crossover of
re-used protein G plates, regenerated once as per
manual and crossover of cleaned and reused
Hypersep diols cartridges was checked with analysis
of three PBS blanks each.
Accuracy (method comparison)
A manual method was performed to recapitulate the
automated method of sample preparation, including
IgG isolation from whole serum, removal of N-linked
glycans from IgG and 2-AB labelling of N-glycans.
The G-ratios of three control concentrations were
compared with those of the automated method
via UPLC.
Recovery of IgG from protein G spin plate
Human serum may typically contain 1118 mg/dL IgG39
or 559 lg per 50 lL. Recovery of washed and eluted
human serum IgG was plotted in duplicate against a
bovine serum albumin standard curve in a Bradford
assay. Three patient samples (two males, one female)
were also tested (Figure 3(f)).
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Interference
Lithium heparin and high bilirubin. A 50 lL control sample
was spiked with 30 lL of each of three high bilirubin
samples extracted from plasma with lithium heparin tubes.
Bilirubin concentrations were 72, 305 and 392lmol/L.
Duplicate G-ratios were checked for reproducibility.
Haemolysis. A 50 lL control sample was spiked with
30 lL of plasma (lithium heparin) containing
Figure 3. (a) Linearity of five concentrations of MAN3–2AB vs. peak area over separate runs. (b) Percentage refrigeration stability of
the control sample over 40 days. (c) Percentage refrigeration stability of a patient sample over 40 days. (d) Stability of the control
sample over four freeze/thaw cycles. (e) Stability of the patient sample over four freeze/thaw cycles. (f) Recovery of IgG from human
serum samples as measured from a bovine serum albumin (BSA) standard curve.
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haemolysed erythrocytes and G-ratios were compared
with 50 lL of control samples spiked with 30 lL
of non-haemolysed serum from the same patient.
The samples were tested in duplicate.
Highly lipaemic. A 50 lL control sample was spiked with
30 lL of highly lipaemic plasma (lithium heparin).
Duplicate G-ratios were checked for reproducibility.
High bilirubin plasma vs. serum. G-ratios from 50lL of
plasma (Lithium heparin) from a patient with 72lmol/L
of bilirubin and 50lL of serum from the same patient
were compared for reproducibility.
Results
The CVs for G0/G1 and G0/G2 were <10% within-
runs (intra-assay) and between-runs (inter-assay) for
both control and patient samples at all concentrations
(Table 1). The combined cumulative CV% of the
100 lL and 50 lL control sample sets was <10%.
The combined cumulative CV of the 100, 50 and
12.5lL control sample sets was less than 20%, a slightly
higher CV as 12.5lL is the LLOQ where congruency of
the G-ratios with higher concentrations begins to wane.
Both the UPLC instrument and sample preparation
platform were tested for linearity. For the UPLC
instrument, the mannose 3–2AB standard supplied
direct from the manufacturer was mixed as a known
solution according to the sample preparation section
and injected. The concentrations of Man3–2AB were
plotted against peak areas showing an R2 value of
0.999 (Figure 3(a)). Therefore, we propose that the
UPLC system presents a linear response between
analytical runs.
For the reportable range of the automated sample
preparation platform, the G-ratio value from serum
samples remained consistently below 10% cumulative
CV from concentrations of 37.5 lL up to 100.0 lL
inclusive (Table 2). With the addition of 12.5 lL
G-ratios (LLOQ), the cumulative CV rose to 14.6%.
The peak areas across all concentrations remained relative-
ly consistent as seen from the average peak areas. Thus, we
suggest a reportable range of 37.5lL to 100lL for the
automated IgG N-glycan purification process.
LLOQ tests were performed on the smallest peaks of
UPLC chromatograms of three 12.5 lL of control sam-
ples. The three EP s/n ratios for the smallest GPs were
all less than 10. The CVs for G0/G1 and G0/G2 ratios
Table 1. Repeatability experiment.
Sample Control sample Patient sample
Concentration (lL)
100.0 50.0 12.5 50.0
G-ratio G0/G1 G0/G2 G0/G1 G0/G2 G0/G1 G0/G2 G0/G1 G0/G2
Run 1 CV% (five replicates) 0.9 3.44 1.79 8.79 0.47 2.82 2.95 5.84
Run 2 CV% (five replicates) 0.42 4.77 0.7 8.7 1.55 3.65 0.58 4.33
Run 3 CV% (five replicates) 0.47 5.92 0.5 3.53 1.48 0.46 2.05 9.03
Run 4 CV% (five replicates) 0.62 4.41 0.36 4.73 2.3 3.08 1.56 2.67
Run 5 CV% (five replicates) 0.55 4.47 0.48 7.37 0.58 1.25 0.92 6.77
Cumulative CV% (25 replicates) 1.35 5.36 0.96 9.43 2.16 3.91 2.18 8.51
Combined cumulative CV%
100 and 50lL (50 replicates)
1.17% for G0/G1 and 7.67% for G0/G2 N/A N/A
Combined cumulative CV%
100, 50 and 12.5lL (75 replicates)
2.05% for G0/G1 and 13.76% for G0/G2 N/A N/A
Note: Each run comprised five replicates at a given concentration. Three concentrations for the control sample (100, 50 and 12.5 lL) and one
concentration for the patient sample (50 lL) was used, thus 20 samples per each run. The values represent the CV% of 5 replicates for both the G0/G1
and G0/G2 ratios. The cumulative CV% row shows the CV over five runs of one control concentration.
CV: coefficient of variation.
Table 2. Reportable range of the method from cumulative CV
percentage.
Control sample concentration







100 lL 0.21 2.52
62.5 lL and 100 lL 0.67 4.69
50 lL, 62.5 lL and 100 lL 0.68 4.99
37.5 lL, 50 lL, 62.5 lL and 100 lL 0.66 5.05
12.5 lL, 37.5 lL, 50.0 lL,
62.5 lL and 100.0 lL
1.39 14.61
CV: coefficient of variation.
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of these samples were less than 10% (see supplement
page 1). Detection limits for volumes lower than
12.5 lL were not measured as 10 lL was the lowest
permissible volume for the protein G plate.
Serum samples and processed N-glycans showed
strong stability. For control samples, CVs of G-ratios
were <20% for the control samples for up to 40 days of
refrigeration (Figure 3(b)). CVs of G-ratios were <10%
for the patient sample up to 40 days of refrigeration
(Figure 3(c)). G-ratios for control samples were stable
and below CV 10% for four freeze–thaw cycles
(Figure 3(d)). For patient samples, CVs of G-ratios
were stable after two cycles, but the CV% rose to
15% for the third and fourth cycles (Figure 3(e)).
Processed N-glycans were tested for intermittent
storage under two conditions from two stages in the
method. Samples tested up to 11 days showed similar
results with CVs <10% when either frozen (40C) or
refrigerated (4C), after (a) glycan release or (b) glycan
dry down (supplement page 2). Upon change of UPLC
column, the control pooled sample and patient serum
samples showed similar results with G-ratio CVs <10%
across all three columns which were used throughout
the study (supplement page 3). Samples in the UPLC
injection dock were stable up to 26 h at 5C. G0/G1
and G0/G2 CV% of a 26 h patient sample were 0.7%
and 0.2%, respectively, compared with the same
sample after 6 h. After this period, peak splitting
began to occur (supplement page 4).
The UPLC profiles indicated that for each of the 28
glycan peaks, after a high sample (100.0 lL of control
sample), areas of blank water sample peaks were virtu-
ally zero, showing little or no crossover in the injection
needle (no peaks to quantify, data not shown). Protein
G wells and Hypersep Cartridges appeared reusable in
the sample preparation step. For PBS blanks ran
through reused (1) protein G wells with reused (1)
Hypersep Diol Cartridges, peak areas were <10% of
the LLOQ when injected after the high sample
(100 lL). For example, the largest blank sample
glycan peaks were 1.09%, 3.29% and 9.61% of the
LLOQ (supplement page 5).
The results of the manual sample preparation exper-
iment showed reproducible G-ratios at three concen-
trations of 12.5, 50.0 and 100.0 lL control samples,
but CVs were higher in some cases. The G0/G1 ratio
CVs were 0.11%, 3.06% and 6.79%, respectively.
The G0/G2 ratio CVs were 3.41%, 11.14% and
24.55%, respectively (supplement page 6).
The recovery of washed IgG from human serum
averaged at 328.8 lg or 58.8% of average values from
the referenced cohort at 559 lg38 or 65.76% of the max-
imum IgG-binding capacity of the resin (500 lg). The
concentrations of the patient IgG samples tested
ranged from 273.5 to 611.5 lg (Figure 3(f)).
The reference ranges for G0/G1 and G0/G2 ratios
were derived from adult patients with classical galacto-
saemia and controls in our previous study.31 For gal-
actosaemia patients, the G0/G1 ratio was 0.75 (0.15),
and for G0/G2, this was 0.95 (0.39). For controls, the
G0/G1 ratio was 0.65 (0.14) and the G0/G2 was 0.78
(0.29).
The environments of clinical apparatus and sample
condition showed good repeatability with serum and
plasma (supplement page 7). The haemolytic plasma
CVs were <10% across four 50.0 lL control samples,
two spiked with haemolytic plasma and two spiked
with non-haemolytic plasma from li-hep tubes.
The CVs for G0/G1 and G0/G2 were 0.4% and
2.1%, respectively. For lipaemic samples (high turbid-
ity), 50.0 lL of control spiked with 30 lL of lipaemic
plasma showed reproducibility at 1.9% and 2.6% CV
for G0/G1 and G0/G2, respectively. High bilirubin
plasma sample CVs were <10% for each duplicate of
72.0, 305.0 and 392.0 lmol/L bilirubin samples which
were spiked at 30.0 lL into 50.0 lL control serum.
The CVs were 1.1%, 0.6%, 0.4% for G0/G1 and
3.1%, 0.3% and 1.9% for G0/G2, respectively. Neat
high bilirubin plasma versus neat serum from a single
patient showed G-ratios with CVs that were not found
to be reproducible which may indicate differing profiles
for plasma samples when tested separately. The neat
serum sample containing high concentrations of biliru-
bin (72 lmol/L) did not show consistent G-ratios which
may indicate some interference at these concentrations.
Discussion
This application of the UPLC method has several
advantages when compared with other available meth-
ods for the diagnosis of N-glycosylation, such as iso-
electric focusing of serum transferrin or tandem mass
spectroscopy.40 It is a well-established, high-through-
put robust analytical technique to obtain high-
resolution separation of N-glycans released from gly-
coproteins.41 N-glycans labelled with a fluorescent label
such as 2-aminobenzamide (2-AB) are detected at fem-
tomole concentrations. The major advantages of
UPLC analysis of fluorescently labelled glycans are
the high reproducibility, exact relative glycan quantifi-
cation and effective separation of structural isomers
and lower cost compared with MS.
Accurate relative glycan quantification and repro-
ducible separation can only be achieved if the glycans
released from glycoproteins are free from contaminants
that may lead to artefacts and poor assay reproducibil-
ity.34 Buffer, detergents, serum contaminants may
interfere with chemical and biochemical reactions.42
In our study, we presumed that the IgG was free
from contaminants and was not prone to any
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interactions. The reasons for omitting the common
analytical interference experiment were the advances
in UPLC preparation technology that allow the effi-
cient removal of buffers, reagents and endogenous car-
bohydrates by washing the immobilized glycoproteins
prior to enzymatic glycan release.43,44 We considered,
however, the possibility of the existence of other
common biological interferants such as haemolytic,
icteric and lipaemic indices. These did not impact
strongly on method reproducibility. However, as seen
in the neat 72 lmoL bilirubin serum samples, samples
from heavily jaundiced patients (>50 lmol/L) may not
show consistent G-ratios.
The repeatability of the method was found to be
optimal with CVs of <10%. CVs of this unique
automated method far exceeded that of the manual
execution. As expected, the manual technique is
flawed and prone to human error.
In other chromatographic methods, recovery would
be normalized and quantified with the use of an IS
which was not possible here as, to our knowledge, no
commercially available IgG with a known quantity of
appended glycans currently exists.45 But importantly,
recovery may vary from run to run, but it does not
have an effect on the IgG N-glycan ‘fingerprint’ of
each sample as seen in the repeatability of the assay.
As this is a qualitative method, ratios of glycan peak
areas relevant to each other are measured, rather
than areas relevant to an IS, i.e. the peaks are self-
calibrating. Peaks were identified as the relevant
glycan units using the UPLC dextran ladder and
glycobase as described in the sample preparation
section. These ratios are consistent and irrespective of
total peak area above certain serum concentrations.
They accurately describe quantitative galactose incor-
poration values when compared with control values.4,11
Further, we have reported the recovery of IgG from
human serum compared with published average
values39 which was improved in this method at an esti-
mated 65.76% compared with 40.0% reported in the
study by Stockmann et al.31 We have also introduced
mannose 3 as a potential IS which showed ideal repeat-
ability in the linearity experiment, did not interfere with
N-glycan peaks and warrants further investigation.
Differential glycosylation patterns in IgG N-glycans
provide a more informative clinical marker in galacto-
saemia compared with the current biochemical tests.
Galactosaemia patients on restricted diet have higher
G0/G1 and G0/G2 ratios compared with healthy indi-
viduals suggesting ongoing glycosylation processing
defects.4,16 Treated galactosaemia patients generally
have increased non-galactosylated (G0) and monoga-
lactosylated (G1) structures, with decreased in certain
digalactosylated (G2) structures compared with healthy
controls.16 In the synthesis of N-glycans, assembly of
core structures occurs in the endoplasmic reticulum,
and processing reactions, such as addition of galactose,
occur in the Golgi apparatus.46 In addition to the
N-glycan processing defects, which we have identified
in all treated adult galactosaemia patients, we have pre-
viously observed that a small subset of patients have
continuing N-glycan assembly defects in addition to
processing defects regardless of treatment with dietary
galactose restriction.16,17 These assembly defects are
mostly limited to galactosaemia untreated neonates,
but can be detected as rare outliers.16,17 For these indi-
viduals (which are outliers), an analysis of the total
serum N-glycome (N-glycans from all proteins in the
serum) in addition to IgG analysis is applicable and
provides a broader analysis of glycan structures
which may be affected. These patients have shown a
deficiency of total branched glycan structures in
addition to poor galactose incorporation.
Galactosaemia appears to be a modifiable galacto-
sylation disorder as demonstrated by different
galactose tolerance levels in patients with identical gen-
otypes.11 Having validated this method and that in
view of the individual G-ratio variation in patients,
we propose that this sensitive and reliable assay can
be applied to personalized monitoring of treatment
interventions for individual patients.
Conclusions
In summary, we present the validation of an automated
high-throughput, low-cost, sensitive and informative
method of IgG N-glycan profiling for classical galacto-
saemia. The method may now potentially be applied to
enable the improved monitoring of patients with
galactosaemia.
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